Researchers believe they may have the next, better version of Ozempic in the works.

At Tufts University, scientists have developed a new drug that aims to boost weight loss while also reducing the nausea, muscle loss, and weight regain associated with popular GLP-1 medications.

The goal is for the “quadruple-action” medication to achieve long-lasting weight loss of up to 30% — matching the effectiveness of bariatric surgery, which reduces the size of the stomach, according to a study press release.

How the drug is different

Semaglutide medications, like Ozempic and Wegovy , mimic the natural hormone GLP‑1 (glucagon‑like peptide‑1), while tirzepatides (such as Mounjaro and Zepbound) target both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors.

The ne

See Full Page